Company Profile
Grifols Stock Price, News & Catalysts
- Ticker:
- GRFS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
7.52 USD (+1.48%)
Close
Last updated: October 6, 2026
5.19B USD
Market cap
Why the stock is moving
As of Oct 6, 2026, GRFS closed up 1.48% at $7.52. No new same-company headline was identified in the current news window.
Company overview
Plasma-Derived Medicines Company
Grifols is a global healthcare company centered on collecting human plasma and manufacturing plasma-derived therapies. Its vertically integrated model links donor-center operations, fractionation capacity, biologics production, and global commercial distribution.
Immunoglobulin and Protein Therapies
The Biopharma portfolio includes immunoglobulins, albumin, alpha-1 antitrypsin therapies, coagulation products, and other specialty plasma proteins. These medicines serve immune deficiencies, neurological disorders, liver disease, bleeding disorders, and other serious conditions.
Plasma Collection Infrastructure
Grifols operates a large donor-center network and is developing additional self-sufficiency platforms, including operations in Egypt and Canada. Control over plasma procurement is central to product availability, manufacturing utilization, and supply resilience.
Diagnostic Technologies
The Diagnostic business provides blood-typing, transfusion-medicine, and clinical-testing solutions. Its portfolio includes instruments, reagents, gel-card systems, and technologies used by blood banks, hospitals, and clinical laboratories.
Bio Supplies Business
Bio Supplies provides plasma-derived proteins, blood components, processed plasma, and clinical samples to pharmaceutical, biotechnology, diagnostic, and research customers. These materials are used in further manufacturing, reagent production, controls, and life-science research.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Grifols (GRFS)?
Grifols (GRFS) most recently closed at 7.52 USD, a +1.48% move versus the previous session.
What is the market cap of Grifols (GRFS)?
Grifols currently has a market capitalization of 5.19B USD on BioPharmSignal.
What does Grifols do?
Plasma-Derived Medicines Company Grifols is a global healthcare company centered on collecting human plasma and manufacturing plasma-derived therapies. Its vertically integrated model links donor-center operations, fractionation capacity, biologics production, and global commercial distribution. Immunoglobulin and Protein Therapies The Biopharma portfolio...
On which exchange is GRFS stock listed?
Grifols (GRFS) is associated with NASDAQ, United States, Biopharma.
What is Plasma-Derived?
Plasma-Derived Medicines Company Grifols is a global healthcare company centered on collecting human plasma and manufacturing plasma-derived therapies.
Which conditions is Grifols targeting with Plasma-Derived?
Plasma-Derived Medicines Company Grifols is a global healthcare company centered on collecting human plasma and manufacturing plasma-derived therapies. Its vertically integrated model links donor-center operations, fractionation capacity, biologics production, and global commercial distribution. Immunoglobulin and Protein Therapies The Biopharma portfolio...
What is Medicines?
Plasma-Derived Medicines Company Grifols is a global healthcare company centered on collecting human plasma and manufacturing plasma-derived therapies.
What is Grifols?
Plasma-Derived Medicines Company Grifols is a global healthcare company centered on collecting human plasma and manufacturing plasma-derived therapies.